Affiliation:
1. Division of Cardiology, Ospedale Umberto I, ASP 4 di Enna, 94100 Enna, Italy
2. Faculty of Medicine and Surgery, Università degli Studi di Enna “Kore”, 94100 Enna, Italy
Abstract
Atherosclerotic cardiovascular disease (ASCVD) represents a major global health challenge, significantly contributing to mortality rates. This chronic inflammatory condition affecting blood vessels is intricately linked to hypercholesterolemia, with elevated levels of low-density lipoprotein cholesterol (LDL-C) recognized as a central and modifiable risk factor. The effectiveness of lipid-lowering therapy (LLT) in mitigating ASCVD risk is well established, with studies revealing a substantial reduction in major ischemic events correlating with LDL-C reduction. While statins, often combined with ezetimibe, remain fundamental in dyslipidemia management, a significant proportion of patients on statin therapy continue to experience cardiovascular events. Recent pharmacological advancements, driven by a deeper understanding of atherogenesis, have unveiled novel therapeutic targets and potent drugs. Notably, agents like bempedoic acid and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (evolocumab, alirocumab, inclisiran) have emerged as effective options to intensify LLT and achieve LDL-C goals, addressing limitations associated with statins, such as myopathy. Molecular insights into alternative pathways have spurred the investigation of emerging agents, offering promising perspectives for novel medications with efficacy comparable to established treatments, associated with advantages in cost and administration. This review provides a comprehensive overview of the evolving landscape of lipid-lowering strategies, highlighting the progress made in addressing ASCVD risk and the potential of upcoming therapies to further optimize cardiovascular prevention.
Reference93 articles.
1. Anti-inflammatory strategies for atherosclerotic artery disease;Agnello;Expert Opin. Drug Saf.,2022
2. Global Burden of Cardiovascular Diseases and Risk actors, 1990–2019: Update from the GBD 2019 Study;Roth;J. Am. Coll. Cardiol.,2020
3. Emerging Risk Factors Collaboration, Di Angelantonio, E., Gao, P., Pennells, L., and Danesh, J. (2012). Lipid-related markers and cardiovascular disease prediction. JAMA, 307, 2499–2506.
4. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., and Collins, R. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376, 1670–1681.
5. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-Analysis;Silverman;JAMA,2016
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献